摘要
目的观察奥氮平联合舒必利治疗难治性精神分裂症的疗效和不良反应。方法对60例难治性精神分裂症患者随机分为合用组和单用组,各30例。合用组给予奥氮平合并舒必利治疗,单用组给予奥氮平治疗,疗程均为12周。采用阳性与阴性症状量表(PANSS)和不良反应量表(TESS)评定疗效和药物不良反应,分别于治疗前及治疗开始后第4、8、12周分别评定1次。结果合用组第8周PANSS总分、阳性症状分均比治疗前明显降低(P<0.05),且12周时降低更为明显(P<0.01);第8周和第12周时阴性症状分及精神病理分较治疗前比较差异有统计学意义(P<0.05)。单用组PANSS总分和阳性、阴性因子分及精神病理分较治疗前比较差异亦有统计学意义(P<0.05或P<0.01)。合用组治疗8周及12周时PANSS总分、阳性症状分均低于单用组,差异有统计学意义(P<0.01或P<0.05)。2组不良反应比较差异无统计学意义(P>0.05)。结论奥氮平联合舒必利治疗难治性精神分裂症,可明显改善阳性症状,疗效较好,不良反应少且依从性好。
Objective To observe the efficacy and adverse reactions of olanzapine combined with sulpiride in refractory schizophrenia.Methods 60 cases patients were randomly divided into combination group and single-use group,each of 30 cases.Combination group were given olanzapine and sulpiride,single-use group were given olanzapine only,the course of treatment all was twelve weeks.The efficiency and adverse reactions were evaluated by positive and negative symptoms scale（PANSS）and treatment emergent symptoms scale（TESS）before and after treatments for 4th、8th、12th week.Results At 8th week,combination group PANSS score,positive symptom score were lower than before treatment（P〈0.05）;And at 12th week,decreased more significantly（P〈0.01）;At 8th and 12th week,negative symptoms and mental pathology scores compared with that before treatment,the difference were significantly significant（P〈0.05）.PANSS,positive symptom,negative symptoms and mental pathology scores in single-use group compared with that before treatment,the difference were significantly significant（P〈0.05 or P〈0.01）.At 8th and 12th week,PANSS,positive symptom scores in combination group were lower than that of single-use group,the difference were statistically significant（P〈0.01 or P〈0.05）.Comparison of adverse reactions of two groups was no significant difference（P〈0.05）.Conclusion Olanzapine combined with sulpiride in refractory schizophrenia,can significantly improve the positive symptoms,has better effect,less adverse reactions and better compliance.
出处
《临床合理用药杂志》
2010年第23期21-22,共2页
Chinese Journal of Clinical Rational Drug Use
